Which of the following is a reversal agent for dabigatran?

Idarucizumab is recognized as a specific reversal agent for dabigatran, which is a direct thrombin inhibitor used in the management of thromboembolic disorders. Dabigatran acts by directly inhibiting thrombin's action, leading to anticoagulation. In cases where rapid reversal of its effects is needed, particularly in situations of urgent surgery or major bleeding, idarucizumab serves as an effective antidote.

Idarucizumab works by binding to dabigatran and its active metabolites with high affinity, effectively neutralizing their anticoagulant effect almost instantaneously. This allows for a rapid restoration of normal clotting function, providing a critical intervention in emergency settings.

In contrast, andexanet alfa is specifically the reversal agent for factor Xa inhibitors, vitamin K is used in the context of warfarin overdose to promote clotting factor synthesis, and protamine sulfate is utilized as an antidote for heparin. None of these options are effective for reversing the action of dabigatran, solidifying idarucizumab's role as the appropriate choice in this scenario.